Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987. |
J. Lapin et al., “Cancer Pain Management with a Controlled Release Oral Morphine Preparation”, Journ. of Pain and Sympton Manag., v 4 (3), pp. 146-151, 1989. |
J. Lapin et al., “Guidelines for use of Controlled Release Oral Morphine in Cancer Pain Management”, Cancer Nursing, v 12 (4), pp. 202-208, 1989. |
R.K. Portenoy, et al., “A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol®Capsules Given Every 24 hours and Every 12 hours with MS Contin®Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain”, Aug. 1992. |
R.F. Kaiko, “The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature”, Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989). |
H.F. Slowey et al., “Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain”, Anaesthesia, 1985, vol. 40, pp. 438-440. |
MS Contin—Frequency of Daily Dosing, Jan.-Nov. 1990. |
Geoffrey K. Gourlay, Ph.D., “The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions”, Journal of Pain and Symptom Management, vol. 6, No. 7, Oct. 1991, pp. 431-436. |
Robert F. Kaiko, et al., “Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food”, The Hospice Journal, vol. 6(4) 1990, pp. 17-30. |
N. Yokokawa, et al., “Relationship between plasma concentration of morphine and analgesic effectiveness”, Postgrad Med J, (1991) 67 (Suppl. 2) pp. 550-554. |
Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824. |
Advertisement: Roxanol SR, ©1988 Roxane Laboratories, Inc. |
R. Kaiko and T. Hunt, “Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulations in Heal Adults”, Clin. Thera., vol. 13, No. 4, 1991. |
R. West and C. Maccarrone, Single Dose Pharmacokinetics of a New Oral Sustained-Release Morphine Formulations, Kapanol®C Abstracts—7th World Congress on Pain, Aug. 26, 1993, Abstracts 997-1001. |
S. Bloomfield, et al., “Analgesic efficacy and potency of two oral controlled-release morphine preparations”, Clin. Pharmacol. Ther., vol. 53, No. 4, pp. 469-478, ©1993. |
Advertisement MS Contin®, ©1987, 198/7, The Purdue Frederick Company. |
Abraham Sunshine, et al., “Analgesic oral efficacy of tramadol hydrochloride in postoperative pain”, Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746. |
E. Beubler, “Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken”, Therapiewoche Osterreich, 7,2(1992), pp. 90-96, with English translation. |
Geoffrey K. Gourlay, Ph.D., et al., “Influence of a high-fat meal on the absorption of morphine from oral solutions”, Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468. |
Robert Kaiko, et al., “A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On the Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets”, Current Therapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878. |
R. West et al. World Congress on Pain Abstracts 997-1001, Aug. 26, 1993. |
Advertisement: Roxanol SR.,®1988 Roxane Labs, Inc. |
R. Kaiko and T. Hunt, Clin. Thera. vol. 13, No. 4, pp. 484-488, 1991. |
S. Bloomfield, et al., Clin. Pharmacol. Ther., vol. 53, No. 4,pp. 469-478,1993. |
Advertisement: MS Contin®1986, 1987 The Purdue Frederick Company. |
MS Contin—Frequency of Daily Dosing (NDTI)—Jun., 1991-May, 1992. |
MS Contin—Frequency of Daily Dosing—Jan.-Nov., 1990. |
Maccarrone C. et al; Single Dose Pharmacokinetics of Kapanol™, a New Oral Sustained-Release Morphine Formulation; Clinical Drug Investigation 1994:7 (5):262-274. |
West R.J. Maccarrone C. Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules. (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file. Glaxo Australia, F.H. Faulding). |
Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol™ (A new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: pharmacokinetic aspects. (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). |
Cherry DA, Gourlay GK, Plummer JL, et al. A comparison of Kapanol™ (a new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: morphine metabolite profiles and renal function. (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993. |
Plummer JL, Cherry DA, Gourlay GK, et al. A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus® and morphine solution in cancer patients: pharmacodynamic aspects. (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). |
Toner G, Cramond T, Bishop J, et al. Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, Kapanol™ capsules, (Abstract 1001) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). |
European Journal of Cancer; Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles; Part A General Topics 1995;31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct.-29 Nov. 2, 1995. |
European Journal of Cancer; Once A Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, In the Treatment of Cancer Pain: Pharmacokinetic Aspects; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897 Eurpean Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. |
European Journal of Cancer; Kadian™/Kapanol™—A Once Daily Morphine Formulation; Part A General Topics 1995;31 (S5) Suppl: S182 Abs 873 European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. |
Gourlay et al., Proceeding of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp 631-643, 1993. |
Kaiko R.F.; Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient; Anesthesiology and Pain Management1991 pp 193-212. |